黑料网

December 24, 2019

GILEAD AND EISAI ENTER INTO AGREEMENT IN JAPAN FOR THE CO-PROMOTION OF THE INVESTIGATIONAL RHEUMATOID ARTHRITIS THERAPY FILGOTINIB, PENDING REGULATORY APPROVAL
Agreement Extends to Additional Potential Indications for Filgotinib, Including Ulcerative Colitis, Crohn鈥檚 Disease and Psoriatic Arthritis

December 23, 2019

U.S. FDA APPROVES EISAI鈥橲 DAYVIGO鈩� (LEMBOREXANT) FOR TREATMENT OF INSOMNIA IN ADULT PATIENTS
OREXIN RECEPTOR ANTAGONIST PROVEN EFFECTIVE FOR BOTH SLEEP ONSET AND SLEEP MAINTENANCE IN CLINICAL DEVELOPMENT PROGRAM OF MORE THAN 2,000 PATIENTS

December 10, 2019

COMMENCEMENT OF MAJOR RENOVATION OF TSUKUBA RESEARCH LABORATORIES AS EISAI GLOBAL DRUG DISCOVERY CENTER AIMING FOR CONNECTING HUMAN AND HUMAN, AND DATA, AND THE WORLD

December 9, 2019

Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer鈥檚 Disease Using Blood
Presenting the Most Recent Data at the 12th Clinical Trials on Alzheimer鈥檚 Disease (CTAD) Conference

December 6, 2019

EISAI SATISFIES ALL-CASE SURVEILLANCE CONDITION FOR APPROVAL OF ANTI-CANCER AGENT LENVIMA庐 IN TREATMENT OF THYROID CANCER

December 5, 2019

EISAI TO PRESENT NEW RESEARCH ON ERIBULIN (HALAVEN庐) AT 42ND ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM

December 2, 2019

EISAI TO PRESENT LATEST DATA ON ALZHEIMER鈥橲 DISEASE / DEMENTIA PIPELINE AT 12TH CLINICAL TRIALS ON ALZHEIMER鈥橲 DISEASE CONFERENCE

December 2, 2019

ADDITIONAL INDICATION FOR LENVIMA庐 (LENVATINIB) FOR DIFFERENTIATED THYROID CANCER ACCEPTED IN CHINA

November 29, 2019

INVESTIGATION REPORT BY MINISTRY OF HEALTH, LABOUR AND WELFARE FOR FATAL CASE IN PHASE I CLINICAL STUDY FOR E2082

November 26, 2019

EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT 73RD AMERICAN EPILEPSY SOCIETY ANNUAL MEETING

November 20, 2019

PARKINSON鈥橲 DISEASE TREATMENT EQUFINA庐 50MG TABLETS (SAFINAMIDE MESILATE) LAUNCHED IN JAPAN

November 5, 2019

EISAI TRANSFERS RIGHTS TO RECEIVE ROYALTIES OUTSIDE OF JAPAN FOR EZH2 INHIBITOR TAZEMETOSTAT TO ROYALTY PHARMA

October 31, 2019

EISAI SUPPORTS RELIEF EFFORTS FOR TYPHOON HAGIBIS

October 22, 2019

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer鈥檚 Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

October 15, 2019

NEW DRUG APPROVAL FOR FYCOMPA庐 FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES IN CHINA

October 1, 2019

Final Study Results Evaluating LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress

September 30, 2019

EISAI AND NICHI-IKO ENTER INTO COLLABORATION AGREEMENT FOR GENERIC PHARMACEUTICAL BUSINESS IN CHINA

September 26, 2019

EISAI AND TOKIO MARINE NICHIDO ENTER INTO BUSINESS ALLIANCE FOR CO-EXISTENCE AND PREVENTION OF DEMENTIA

September 26, 2019

EISAI AND FRONTEO TO LAUNCH COROBAN庐銆�
TUMBLING AND FALLING PREDICTION SYSTEM FOR INPATIENTS

September 24, 2019

EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO 2019 CONGRESS

September 20, 2019

EISAI AND MEIJI ANNOUNCE PARKINSON鈥橲 DISEASE TREATMENT EQUFINA庐 TABLETS (SAFINAMIDE MESILATE) APPROVED IN JAPAN

September 20, 2019

PROMOTION AND DISTRIBUTION AGREEMENT WITH MYLAN INDIA FOR ERIBULIN SECOND BRAND IN INDIA
AIMING TO EXPAND AVAILABILITY TO PATIENTS IN INDIA WITH TWO BRANDS HALAVEN庐 AND TECERIS庐

September 19, 2019

EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT WORLD SLEEP CONGRESS

September 18, 2019

EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY
ASIA PACIFIC INDEX 2019 FOR SIXTH TIME

September 18, 2019

FDA Approves LENVIMA庐 (lenvatinib) plus KEYTRUDA庐 (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Who Have Disease Progression Following Prior Systemic Therapy and Are Not Candidates for Curative Surgery or Radiation
Under New FDA-Initiated Program, Combination Treatment Is the First to Receive Simultaneous Review Decisions in the U.S., Australia and Canada

September 17, 2019

EISAI RECEIVES IIA JAPAN CHAIRMAN鈥橲 AWARD OF INSTITUTE OF INTERNAL AUDITORS - JAPAN

September 13, 2019

EISAI AND BIOGEN TO DISCONTINUE PHASE III CLINICAL STUDIES OF BACE INHIBITOR ELENBECESTAT IN EARLY ALZHEIMER鈥橲 DISEASE
Discontinuation of studies based on Data Safety Monitoring Board recommendation

August 29, 2019

ALCOHOL-FREE WIPE FOR ELIMINATING VIRUSES AND BACTERIA ON PERSONAL BELONGINGS
EISAI TO LAUNCH NEW 鈥淓TAK庐 ANTIMICROBIAL WET WIPES鈥� WITH ONE WEEK LASTING ANTIMICROBIAL ACTION

August 28, 2019

EISAI ENTERS INTO BUSINESS ALLIANCE WITH COGSTATE FOR EXCLUSIVE DEVELOPMENT AND COMMERCIALIZATION OF A DIGITAL TOOL FOR SELF-ASSESSMENT OF COGNITIVE FUNCTION IN JAPAN

August 27, 2019

EISAI PROVIDES TANKS TO SUPPLY CLEAN WATER TO NEGLECTED TROPICAL DISEASES ENDEMIC REGIONS IN KENYA, IN COLLABORATION WITH MERCK

August 1, 2019

ALWAYS CLOSE TO YOU. QUICKLY ABSORBING AND NON STICKY
EISAI TO REFRESH AND LAUNCH SAHNE庐 CREAM AFTER 20 YEARS
WITH MILD SCENT AND NEW PACKAGE

July 31, 2019

Notice Regarding Revisions of Dividend Forecasts for Fiscal Year Ending March 31, 2020 (DIVIDEND INCREASE)

July 30, 2019

Fatality in Phase I Clinical Study of E2082

July 23, 2019

黑料网 and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA for LENVIMA庐 (lenvatinib) plus KEYTRUDA庐 (pembrolizumab) Combination Treatment
as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment

July 19, 2019

LATEST TRENDS OF TREATMENT FOR ALZHEIMER鈥橲 DISEASE IN SESSIONS AND SYMPOSIUM AT ALZHEIMER鈥橲 ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2019

July 19, 2019

EISAI PRESENTS DATA SHOWING QUANTIFICATION OF TAU MICROTUBULE BINDING REGION IN CEREBROSPINAL FLUID AND THE IDENTIFICATION OF A TARGET ENGAGEMENT BIOMARKER FOR THE NEW ANTI-TAU ANTIBODY E2814 AT ALZHEIMER鈥橲 ASSOCIATION INTERNATIONAL CONFERENCE (AAIC)2019

July 18, 2019

EISAI PRESENTS RESEARCH EVALUATING CORRELATION OF HIGHLY-PRECISELY MEASURED AMYLOID BETA IN PLASMA AND CEREBROSPINAL FLUID WITH NEWLY DEVELOPED AUTOMATED PROTEIN ASSAY SYSTEM AT ALZHEIMER鈥橲 ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2019

July 18, 2019

EISAI PRESENTS NONCLINICAL RESEARCH RESULTS OF ELENBECESTAT OF WITHOUT SIGNIFICANT EFFECTS ON SYNAPTIC FUNCTION IN BRAIN BY SPINAL DENSITIY EVALUATION AT EFFECTIVE DOSE TO DECREASE AMYLOID BETA LEVEL IN CEREBROSPINAL FLUID AT AAIC 2019

July 17, 2019

ANTICANCER AGENT HALAVEN庐 APPROVED FOR TREATMENT OF LOCALLY ADVANCED OR METASTATIC BREAST CANCER IN CHINA

July 11, 2019

EISAI LISTED FOR 18TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT

July 11, 2019

LATEST DATA ON EISAI鈥橲 ALZHEIMER鈥橲 DISEASE / DEMENTIA PIPELINE TO BE PRESENTED AT ALZHEIMER鈥橲 ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2019

July 10, 2019

EISAI CENTER FOR GENETICS GUIDED DEMENTIA DISCOVERY COMMENCES FULL-SCALE OPERATION TOWARD INNOVATIVE DEMENTIA TREATMENTS WITH NEW DRUG DISCOVERY APPROACH IN CAMBRIDGE, MASSACHUSETTS
A FOCUSED DRUG DISCOVERY APPROACH THAT INTEGRATES HUMAN GENETICS / DATA SCIENCE / PRECISION CHEMISTRY

July 8, 2019

EISAI ENTERS INTO COLLABORATION RESEARCH AGREEMENT WITH UNIVERSITY OF DUNDEE ON TARGETED PROTEIN DEGRADATION TOWARD CANCER DRUG DISCOVERY

June 27, 2019

Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares

June 21, 2019

SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS

June 20, 2019

CONTINUATION OF 鈥淧OLICY FOR PROTECTION OF THE COMPANY鈥橲 CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (COUNTERMEASURES AGAINST TAKEOVERS)鈥�

June 17, 2019

TOTAL SYNTHESIS AND NONCLINICAL STUDY RESULTS OF A NOVEL ANTICANCER DRUG CANDIDATE E7130 DERIVED FROM TOTAL SYNTHESIS OF HALICHONDRIN FOUND IN JOINT RESEARCH BETWEEN EISAI AND HARVARD UNIVERSITY SCIENTISTS, PUBLISHED IN SCIENTIFIC REPORTS

June 14, 2019

EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT 33RD INTERNATIONAL EPILEPSY CONGRESS

May 29, 2019

EISAI TO PRESENT LATEST DATA ON LEMBOREXANT INCLUDING INTEGRATED ANALYSIS OF PHASE III CLINICAL STUDIES AT 33RD ANNUAL SLEEP MEETING

May 17, 2019

鈥淪CIENCE BASED TARGETS (SBT) INITIATIVE鈥� APPROVES EISAI鈥橲 GREENHOUSE GAS REDUCTION TARGETS

May 16, 2019

EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT 55TH ASCO ANNUAL MEETING

May 13, 2019

Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Continuation of the Performance-Related Stock-Based Compensation System

May 13, 2019

Notification Regarding the Continuation of the Performance-Related Stock-Based Compensation System

May 13, 2019

Notification Regarding Change in Representative Corporate Officers

May 10, 2019

EISAI ENTERS INTO LICENSING AGREEMENT WITH MEDAC CONCERNING ANTI-RHEUMATIC AGENT METHOTREXATE SUBCUTANEOUS INJECTION IN JAPAN

May 10, 2019

Alzheimer鈥檚 Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer鈥檚 Disease

May 9, 2019

黑料网 and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions

May 9, 2019

EISAI COMMENCES VENTURE INVESTMENT BUSINESS AIMED AT ACCELERATING INNOVATION IN DRUG CREATION AND ESTABLISHMENT OF ECOSYSTEM PLATFORM

May 8, 2019

EISAI AND UK DEMENTIA RESEARCH INSTITUTE JOINTLY LAUNCH NEW POST-DOCTORAL PROGRAMME TO ACCELERATE DEMENTIA RESEARCH

May 1, 2019

EISAI BUYS OUT PURDUE RIGHTS TO END COLLABORATION
EISAI TO CONTINUE TO DEVELOP AND COMMERCIALIZE LEMBOREXANT GLOBALLY

April 24, 2019

EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AND PERAMPANEL AT ANNUAL AMERICAN ACADEMY OF NEUROLOGY MEETING

April 24, 2019

EISAI SELECTED AS COMPETITIVE ICT STRATEGY COMPANY 2019
RECOGNIZED FOR TAKING ON CHALLENGE OF TRANSFORMATION TO NEW BUSINESS MODELS BY INTEGRATING MANAGEMENT AND ICT STRATEGIES

April 8, 2019

JAPAN MHLW GRANTS SAKIGAKE DESIGNATION TO NOVEL FIBROBLAST GROWTH FACTOR (FGF) RECEPTOR SELECTIVE TYROSINE KINASE INHIBITOR E7090

April 8, 2019

START YOUR DAY WITH A SPARKLING POP!
EISAI TO LAUNCH CHOCOLA BB庐 SPARKLING KIWI & LEMON FLAVOR
CONTAINING 75 LEMONS WORTH OF VITAMIN C AND 50% LESS CALORIES!

April 5, 2019

鈥淔OR MOTION SICKNESS AND DISCOMFORT鈥�
EISAI TO LAUNCH 鈥淭RAVELMIN庐 SUPPORT鈥� AS SERIES鈥� FIRST QUASI-DRUG
MOTION SICKNESS SOLUTION NOW AVAILABLE IN CONVENIENCE STORES

April 1, 2019

NICHI-IKO PHARMACEUTICAL AND EISAI COMMENCE CO-PROMOTION OF NICHI-IKO PRODUCTS AND COLLABORATION ON EISAI鈥橲 INTEGRATED PACKAGE STRATEGIES

March 29, 2019

DATA SAFETY MONITORING BOARD RECOMMENDS CONTINUATION OF PHASE III CLINICAL STUDIES OF BACE INHIBITOR ELENBECESTAT IN EARLY ALZHEIMER鈥橲 DISEASE

March 22, 2019

INITIATION OF PHASE III CLINICAL TRIAL OF BAN2401 IN EARLY ALZHEIMER鈥橲 DISEASE

March 22, 2019

EISAI TO PRESENT LATEST RESEARCH ON ALZHEIMER鈥橲 DISEASE / DEMENTIA PIPELINE AT THE 14TH INTERNATIONAL CONFERENCE ON ALZHEIMER鈥橲 & PARKINSON鈥橲 DISEASES

March 21, 2019

Biogen and 黑料网 to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer鈥檚 Disease
Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials

March 12, 2019

黑料网 and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia

March 7, 2019

MARKETING AUTHORIZATION APPLICATION FOR POTENTIAL INSOMNIA DISORDER TREATMENT LEMBOREXANT SUBMITTED IN JAPAN

February 27, 2019

EISAI ENTERS INTO AGREEMENT TO SUPPORT INTERNATIONAL NGO ASSOCIATION FOR AID AND RELIEF, JAPAN鈥橲 ACTIVITIES IN SUDAN
CONTRIBUTING FURTHER TO PATIENTS WITH MYCETOMA, A NEGLECTED TROPICAL DISEASE

February 21, 2019

AbbVie and 黑料网 Announce Fully Human Anti-TNF-伪 Monoclonal Antibody HUMIRA庐 is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa

February 13, 2019

EISAI SUBMITS APPLICATION IN EUROPE SEEKING APPROVAL FOR FYCOMPA庐 AS TREATMENT FOR PEDIATRIC PATIENTS WITH EPILEPSY

February 4, 2019

黑料网 and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study at the Sleep Research Society鈥檚 Conference: Advances in Sleep and Circadian Science
Six-month data show significant improvements in patient-reported measures of sleep onset and sleep maintenance for investigational agent lemborexant

January 30, 2019

SUPPLEMENTARY NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR FYCOMPA庐 AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES, AS WELL AS NEW FORMULATION

January 22, 2019

EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE FOURTH TIME
HIGHEST RANKED JAPANESE COMPANY

January 18, 2019

Notification Regarding Results of Voluntary Retirement Program

January 15, 2019

New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States

January 15, 2019

EISAI TO PRESENT RESULTS OF POST-HOC ANALYSES OF LENVIMA庐 (LENVATINIB) PHASE III REFLECT STUDY IN HEPATOCELLULAR CARCINOMA AT 2019 GASTROINTESTINAL CANCERS SYMPOSIUM

January 4, 2019

FOR DEALING WITH VIRUSES AND BACTERIA! ANTIMICROBIAL BARRIER THAT LASTS FOR 1 WEEK 鈥淓TAK庐 ANTIMICROBIAL SPRAY伪鈥� WINS NIKKEI BUSINESS DAILY AWARDS FOR SUPERIORITY AT THE 2018 NIKKEI SUPERIOR PRODUCTS AND SERVICES AWARDS

January 4, 2019

NEW DRUG APPLICATION FOR PERAMPANEL DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES